Form 4: Akero Therapeutics Executive Sells Shares to Cover Tax Obligations

Akero Therapeutics Senior VP, Commercial Strategy, Patrick Lamy, sold 925 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, sold 925 shares of common stock on December 10, 2024.
• The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
• The shares were sold at a weighted-average price of $30.79, with individual transactions ranging from $30.79 to $31.04.
• Following the transaction, Lamy directly owns 17,858 shares of Akero Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document describes a routine transaction for an executive to cover tax obligations. It is neither positive nor negative for the company's outlook.

Industry Context

This is a routine transaction for executives who receive stock-based compensation. It is common for executives to sell shares to cover tax obligations when restricted stock units vest.

Comparison to Industry Standards

• Sales of shares by executives to cover tax obligations are a common practice across the industry.
• The sale was conducted under a 'sell-to-cover' policy, which is a standard procedure for managing tax liabilities related to stock-based compensation.
• The price range of $30.79 to $31.04 is within the typical trading range for the stock at the time of the transaction.

Stakeholder Impact

• The sale has a minimal impact on shareholders as it is a routine transaction for tax purposes.

Key Dates

Keywords

Akero Therapeutics, stock sale, insider trading, Form 4, restricted stock units, tax obligations, equity securities